Shots:
- Styx Biotechnologies has entered into a strategic agreement with ZoeNCure Therapeutics to accelerate selected Styx ADC programs toward first-in-human clinical studies for multiple solid tumor indications
- The collaboration gives Styx a capital-efficient path to advance selected ADC assets through coordinated preclinical, CMC, regulatory & clinical activities while preserving opportunities for global development & strategic partnering
- As per the deal, Styx will receive an upfront payment & milestone-based payments, while ZoeNCure will fund development & provide clinical infrastructure for early-phase studies; additional financial terms were not disclosed
Ref: PRnewswire | Image: Styx & ZoeNCure | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
